Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Change in Cash: 2009-2024

Historic Change in Cash for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to $10.4 million.

  • Lineage Cell Therapeutics' Change in Cash rose 3.54% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.7 million, marking a year-over-year increase of 443.02%. This contributed to the annual value of $10.4 million for FY2024, which is 56.93% down from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Change in Cash stood at $10.4 million for FY2024, which was down 56.93% from $24.1 million recorded in FY2023.
  • In the past 5 years, Lineage Cell Therapeutics' Change in Cash ranged from a high of $24.1 million in FY2023 and a low of -$44.3 million during FY2022.
  • In the last 3 years, Lineage Cell Therapeutics' Change in Cash had a median value of $10.4 million in 2024 and averaged -$3.3 million.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Change in Cash spiked by 261.41% in 2020, and later tumbled by 292.00% in 2022.
  • Yearly analysis of 5 years shows Lineage Cell Therapeutics' Change in Cash stood at $23.1 million in 2020, then increased by 0.03% to $23.1 million in 2021, then slumped by 292.00% to -$44.3 million in 2022, then surged by 154.25% to $24.1 million in 2023, then slumped by 56.93% to $10.4 million in 2024.